Zobrazeno 1 - 10
of 16
pro vyhledávání: '"Ashesh, Gandhi"'
Publikováno v:
Therapeutic Advances in Vaccines and Immunotherapy, Vol 8 (2020)
Influenza continues to cause severe illness in millions and deaths in hundreds of thousands annually. Vaccines are used to prevent influenza outbreaks, however, the influenza virus mutates and annual vaccination is required for optimal protection. Va
Externí odkaz:
https://doaj.org/article/8f517fb03627442faaa044d4992f0b3b
Publikováno v:
Infection and Drug Resistance. 10:401-417
Background Acinetobacter infections, especially multidrug-resistant (MDR) Acinetobacter infections, are a global health problem. This study aimed to describe clinical outcomes in patients with confirmed Acinetobacter spp. isolates who were treated wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::07cf562e3b5ed65262df146ec1e624cc
https://doi.org/10.2147/idr.s143306
https://doi.org/10.2147/idr.s143306
Autor:
Katia Bruxvoort, Hung Fu Tseng, Yi Luo, Bradley Ackerson, Ashesh Gandhi, Hilary C. Tanenbaum, Lina S. Sy
Publikováno v:
Vaccine. 37(39)
Egg-based influenza vaccines could be less effective than cell-based vaccine due to adaptive mutations acquired for growth. We conducted a test-negative case-control study at Kaiser Permanente Southern California to assess vaccine effectiveness (VE)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d7d9e0d511c956b1e4d5de0efbfbe97
https://pubmed.ncbi.nlm.nih.gov/31445771
https://pubmed.ncbi.nlm.nih.gov/31445771
Publikováno v:
Postgraduate Medicine. 128:548-556
Neisseria meningitidis is a common cause of bacterial meningitis, often leading to permanent sequelae or death. N. meningitidis is classified into serogroups based on the composition of the bacterial capsular polysaccharide; the 6 major disease-causi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7a8a9b240adcc90fe817c8093f0a3027
https://doi.org/10.1080/00325481.2016.1203238
https://doi.org/10.1080/00325481.2016.1203238
Publikováno v:
Therapeutic Advances in Vaccines and Immunotherapy, Vol 8 (2020)
Therapeutic Advances in Vaccines and Immunotherapy
Therapeutic Advances in Vaccines and Immunotherapy
Influenza continues to cause severe illness in millions and deaths in hundreds of thousands annually. Vaccines are used to prevent influenza outbreaks, however, the influenza virus mutates and annual vaccination is required for optimal protection. Va
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ca0b6d3209cfc2978f6f1ea0600a1cf
https://doi.org/10.1177/2515135520908121
https://doi.org/10.1177/2515135520908121
Publikováno v:
The Journal of Clinical Pharmacology. 54:513-519
Safety, tolerability, and pharmacokinetics of tigecycline in 76 healthy Japanese subjects were determined in three randomized, double-blind, placebo-controlled studies. Subjects in an ascending single-dose study (n = 40) received 25-150 mg intravenou
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f7341ad981ad67f4313ae31dded06ed
https://doi.org/10.1002/jcph.236
https://doi.org/10.1002/jcph.236
Publikováno v:
Pharmacotherapy. 36(8)
Invasive meningococcal disease caused by Neisseria meningitidis presents a significant public health concern. Meningococcal disease is rare but potentially fatal within 24 hours of onset of illness, and survivors may experience permanent sequelae. Th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::89846850c81ed26be24735771775d656
https://pubmed.ncbi.nlm.nih.gov/27332671
https://pubmed.ncbi.nlm.nih.gov/27332671
Publikováno v:
Infection and Drug Resistance, Vol Volume 10, Pp 401-417 (2017)
Hal Tucker, Michele Wible, Ashesh Gandhi, Alvaro QuintanaPfizer Inc, Collegeville, PA, USABackground: Acinetobacter infections, especially multidrug-resistant (MDR) Acinetobacter infections, are a global health problem. This study aimed to describe c
Externí odkaz:
https://doaj.org/article/1ef4d859f92442ca8174aa29fa6d9e5d
Characteristics of a new meningococcal serogroup B vaccine, bivalent rLP2086 (MenB-FHbp; Trumenba®).
Publikováno v:
Postgraduate Medicine; Aug2016, Vol. 128 Issue 6, p548-556, 9p
Publikováno v:
Pharmacotherapy; Aug2016, Vol. 36 Issue 8, p880-892, 13p